MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 574232 | Name: PAQ
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PAQ is a neuroprotective agent. It protects dopaminergic neurons from cell death without inhibiting glial cell proliferation. PAQ prevents loss of dopaminergic neurons in the substantia nigra in a mouse model of Parkinson’s disease induced by MPTP.

Chemical Structure

PAQ
PAQ
CAS#943902-10-1

Theoretical Analysis

MedKoo Cat#: 574232

Name: PAQ

CAS#: 943902-10-1

Chemical Formula: C14H11N3

Exact Mass: 221.0953

Molecular Weight: 221.26

Elemental Analysis: C, 76.00; H, 5.01; N, 18.99

Price and Availability

Size Price Availability Quantity
1mg USD 215.00
5mg USD 445.00
10mg USD 725.00
25mg USD 1,400.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
PAQ
IUPAC/Chemical Name
3-phenyl-6-quinoxalinamine
InChi Key
BTTJRYBJJULOGN-UHFFFAOYSA-N
InChi Code
InChI=1S/C14H11N3/c15-11-6-7-12-13(8-11)17-14(9-16-12)10-4-2-1-3-5-10/h1-9H,15H2
SMILES Code
NC1=CC=C(N=CC(C2=CC=CC=C2)=N3)C3=C1
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
PAQ is a neuroprotective agent.
In vitro activity:
Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder. Reference: J Med Chem. 2016 Jul 14;59(13):6169-86. https://pubmed.ncbi.nlm.nih.gov/27341519/
In vivo activity:
Neuroprotection assessment in PD cellular models of our newly synthesized quinoxaline-derived compounds has led to the selection of a better hit compound, PAQ (4c). Extensive in vitro characterization of 4c showed that its neuroprotective action is partially attributable to the activation of reticulum endoplasmic ryanodine receptor channels. Most interestingly, 4c was able to attenuate neurodegeneration in a mouse model of PD, making this compound an interesting drug candidate for the treatment of this disorder. Reference: J Med Chem. 2016 Jul 14;59(13):6169-86. https://pubmed.ncbi.nlm.nih.gov/27341519/
Solvent mg/mL mM
Solubility
DMF 10.0 45.20
DMSO 10.0 45.20
DMSO:PBS (pH 7.2) (1:1) 0.5 2.26
Ethanol 2.0 9.04
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 221.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B. New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. J Med Chem. 2016 Jul 14;59(13):6169-86. doi: 10.1021/acs.jmedchem.6b00297. Epub 2016 Jul 5. PMID: 27341519.
In vitro protocol:
Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B. New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. J Med Chem. 2016 Jul 14;59(13):6169-86. doi: 10.1021/acs.jmedchem.6b00297. Epub 2016 Jul 5. PMID: 27341519.
In vivo protocol:
Le Douaron G, Ferrié L, Sepulveda-Diaz JE, Amar M, Harfouche A, Séon-Méniel B, Raisman-Vozari R, Michel PP, Figadère B. New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. J Med Chem. 2016 Jul 14;59(13):6169-86. doi: 10.1021/acs.jmedchem.6b00297. Epub 2016 Jul 5. PMID: 27341519.
1. Le Douaron, G., Ferrié, L., Sepulveda-Diaz, J.E., et al. New 6-aminoquinoxaline derivatives with neuroprotective effect on dopaminergic neurons in cellular and animal parkinson disease models. J. Med. Chem. 59(13), 6169-6186 (2016).